Skip to main content
. 2016 Jan 22;6:19817. doi: 10.1038/srep19817

Figure 2. Topical tacrolimus decreases perilymphatic inflammation in obese mice.

Figure 2

(a) Representative high power photomicrographs (40x) and quantification of (b) perilymphatic inflammation in hindlimb sections stained for CD45 (green) and LYVE-1 (red; n = 5 animals with 4–5 HPF/animal, p < 0.01). (c) Hindlimb tissues assessed using flow cytometry to identify CD45+ cells as a percentage of live cells (p < 0.05). (d) Representative high power photomicrographs (80x) and quantification of (e) perilymphatic inflammation in hindlimb sections stained for CD11b (green) and LYVE-1 (red; n = 5 animals with 4–5 HPF/animal, p < 0.01). (f) Hindlimb tissues assessed using flow cytometry to identify macrophages (CD11b+/CD45+) as a percentage of total live cells (n = 4 animals/group, p < 0.01). (g) Representative high power photomicrographs (40x) and quantification of (h) perilymphatic inflammation in dermal hindlimb sections stained for CD4 (green) and LYVE-1 (red; n = 5 animals with 4–5 HPF/animal, p < 0.05). (i) Hindlimb tissues assessed using flow cytometry to identify T helper cells (CD4+/CD3+/CD45+) as a percentage of total live cells (p < 0.01).